In early August, Triangle Pharmaceuticals Inc.'s stock shot up surrounding favorable interim data from a Phase III trial of the company's lead product candidate for HIV. And Thursday, the stock was up ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results